Clinical Trial Update: The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States. [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating oral oxcarbazepine as adjuvant therapy for bipolar disorder I or II (not conducted in the United States) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Oxcarbazepine (Oxcarbazepine)

Snippet

Sponsor: Novartis | Conditions: Bipolar Disorder | Phase 4 | Status: COMPLETED